GH Research (NASDAQ:GHRS – Get Free Report)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a report issued on Tuesday,Benzinga reports. They currently have a $39.00 price objective on the stock. JMP Securities’ price objective would indicate a potential upside of 228.01% from the stock’s current price.
A number of other equities analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of GH Research in a research report on Friday, May 9th. Cantor Fitzgerald assumed coverage on shares of GH Research in a research report on Wednesday, June 4th. They issued an “overweight” rating and a $25.00 target price on the stock. Wall Street Zen cut shares of GH Research from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. Royal Bank Of Canada assumed coverage on shares of GH Research in a research report on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price on the stock. Finally, Stifel Nicolaus lifted their target price on shares of GH Research from $18.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, GH Research has a consensus rating of “Moderate Buy” and an average target price of $32.00.
View Our Latest Analysis on GHRS
GH Research Stock Performance
GH Research (NASDAQ:GHRS – Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.42. On average, analysts predict that GH Research will post -0.8 earnings per share for the current year.
Institutional Investors Weigh In On GH Research
Large investors have recently modified their holdings of the stock. RA Capital Management L.P. boosted its stake in GH Research by 3.9% during the first quarter. RA Capital Management L.P. now owns 6,944,648 shares of the company’s stock worth $76,599,000 after acquiring an additional 257,959 shares in the last quarter. Lynx1 Capital Management LP lifted its stake in shares of GH Research by 15.8% in the fourth quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after buying an additional 663,100 shares in the last quarter. Cormorant Asset Management LP lifted its stake in shares of GH Research by 238.8% in the first quarter. Cormorant Asset Management LP now owns 2,009,482 shares of the company’s stock worth $22,165,000 after buying an additional 1,416,439 shares in the last quarter. Jefferies Financial Group Inc. bought a new position in shares of GH Research in the first quarter worth approximately $8,272,000. Finally, Alyeska Investment Group L.P. bought a new position in shares of GH Research in the first quarter worth approximately $5,018,000. Institutional investors own 56.90% of the company’s stock.
GH Research Company Profile
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Recommended Stories
- Five stocks we like better than GH Research
- How to invest in marijuana stocks in 7 steps
- Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
- Top Stocks Investing in 5G Technology
- ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.